Posts

Ordaōs and NonExomics announced a research pact to develop mini-proteins, called miniPROs, for three specific difficult-to-target rare cancers.

At the American Society of Clinical Oncology (ASCO)’s annual meeting this weekend, BioNTech and Dr. Vinod Balachandran, M.D. of Memorial Sloan Kettering Cancer Center, presented preliminary Phase I data of its BNT122, which it is evaluating with Genentech (Roche) in pancreatic cancer.

Shares of Repare Therapeutics soared more than 27 percent in premarket trading on June 2 following the previous day’s announcement of a global cancer collaboration valued at up to $1.2 billion with Swiss pharma giant Roche for the development and commercialization of camonsertib.